PA8618401A1 - Prevencion y tratamiento de enfermedades cardiacas hipertensivas mediante el uso de los estrogenos selectivos 8beta-vinil-estra-1,3,5(10)-trien-3,17beta-diol y 17beta-fluor-9alfa-vinil-estra-1.3,5(10)-trien-3,16alfa-diol - Google Patents

Prevencion y tratamiento de enfermedades cardiacas hipertensivas mediante el uso de los estrogenos selectivos 8beta-vinil-estra-1,3,5(10)-trien-3,17beta-diol y 17beta-fluor-9alfa-vinil-estra-1.3,5(10)-trien-3,16alfa-diol

Info

Publication number
PA8618401A1
PA8618401A1 PA20048618401A PA8618401A PA8618401A1 PA 8618401 A1 PA8618401 A1 PA 8618401A1 PA 20048618401 A PA20048618401 A PA 20048618401A PA 8618401 A PA8618401 A PA 8618401A PA 8618401 A1 PA8618401 A1 PA 8618401A1
Authority
PA
Panama
Prior art keywords
vinil
17beta
estra
trien
diol
Prior art date
Application number
PA20048618401A
Other languages
English (en)
Inventor
Karl Heinrich Fritzemeier
Krista Hegele-Hartung
Ludwig Neyse
Theo Pelzer
Olaf Peters
Original Assignee
Sschering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sschering Ag filed Critical Sschering Ag
Publication of PA8618401A1 publication Critical patent/PA8618401A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

USO DE LOS AGONISTAS DE ER-BETA 8BETA-VINIL-ESTRA -1,3,5(10)-TRIEN-3,17BETA-DIOL Y 17BETA -FLOUR-9ALPHA-VINIL-ESTRA-1,3,5 (10)-TRIEN-3,16ALPHA-DIOL PARA PRODUCIR MEDICAMENTO PARA LA PREVENCION Y/O EL TRATAMIENTO DE ENFERMEDADES CARDIACAS HIPERTENSIVAS, ESPECIALMENTE PARA LA PREVENCION Y/O EL TRATAMIENTO DE UNA O MAS DE LAS CONDICIONES SELECCIONADAS DEL GRUPO QUE CONSISTE EN (1) HIPERTENSION), (2) HIPERTROFIA CARDIACA Y (3) DEFICIENCIA CARDIACA.
PA20048618401A 2003-11-26 2004-11-25 Prevencion y tratamiento de enfermedades cardiacas hipertensivas mediante el uso de los estrogenos selectivos 8beta-vinil-estra-1,3,5(10)-trien-3,17beta-diol y 17beta-fluor-9alfa-vinil-estra-1.3,5(10)-trien-3,16alfa-diol PA8618401A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03090406 2003-11-26

Publications (1)

Publication Number Publication Date
PA8618401A1 true PA8618401A1 (es) 2005-08-04

Family

ID=34626396

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20048618401A PA8618401A1 (es) 2003-11-26 2004-11-25 Prevencion y tratamiento de enfermedades cardiacas hipertensivas mediante el uso de los estrogenos selectivos 8beta-vinil-estra-1,3,5(10)-trien-3,17beta-diol y 17beta-fluor-9alfa-vinil-estra-1.3,5(10)-trien-3,16alfa-diol

Country Status (16)

Country Link
US (1) US20050148560A1 (es)
EP (1) EP1689410B1 (es)
JP (1) JP2007512279A (es)
AR (1) AR046672A1 (es)
AT (1) ATE395919T1 (es)
DE (1) DE602004014020D1 (es)
DK (1) DK1689410T3 (es)
ES (1) ES2307064T3 (es)
GT (1) GT200400241A (es)
PA (1) PA8618401A1 (es)
PE (1) PE20050665A1 (es)
PL (1) PL1689410T3 (es)
PT (1) PT1689410E (es)
TW (1) TW200530263A (es)
UY (1) UY28630A1 (es)
WO (1) WO2005051401A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10027887A1 (de) 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US7534780B2 (en) 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
DE102005057224A1 (de) * 2005-11-29 2007-05-31 Bayer Schering Pharma Ag Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
TWI389917B (zh) * 2006-04-13 2013-03-21 Sigma Tau Ind Farmaceuti 作為心血管疾病治療藥物的雄甾烷與雄甾烯之氮雜環烷基衍生物
TWI392682B (zh) * 2006-04-13 2013-04-11 Sigma Tau Ind Farmaceuti 作為心血管疾病的治療藥物之雄甾烷和雄甾烯的胺基衍生物
WO2008091555A2 (en) 2007-01-22 2008-07-31 Gtx, Inc. Nuclear receptor binding agents
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
EP2143432A1 (en) * 2008-07-11 2010-01-13 Bayer Schering Pharma AG 9-alpha estratriene derivatives as ER-beta selective ligands for the prevention and treatment of intestinal cancer
WO2011079047A1 (en) * 2009-12-23 2011-06-30 Drugtech Corporation Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
US9844558B1 (en) 2015-04-30 2017-12-19 Amag Pharmaceuticals, Inc. Methods of reducing risk of preterm birth
US10556922B2 (en) 2015-09-29 2020-02-11 Amag Pharmaceuticals, Inc. Crystalline and amorphous forms of 17-alpha-hydroxyprogesterone caproate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10019167A1 (de) * 2000-04-12 2001-10-18 Schering Ag Substituierte Estratriene als selektiv wirksame Estrogene
AU2001258341B2 (en) * 2000-04-12 2007-03-15 Schering Aktiengesellschaft 8beta-hydrocarbyl-substituted estratrienes for use as selective estrogens
GB2374412A (en) * 2001-04-11 2002-10-16 Karobio Ab Hypertension treatment and assay
US7414043B2 (en) * 2002-06-11 2008-08-19 Schering Ag 9-α-substituted estratrienes as selectively active estrogens
DE10226326A1 (de) * 2002-06-11 2004-01-15 Schering Ag 9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene

Also Published As

Publication number Publication date
ES2307064T3 (es) 2008-11-16
JP2007512279A (ja) 2007-05-17
PT1689410E (pt) 2008-08-18
EP1689410A2 (en) 2006-08-16
DK1689410T3 (da) 2008-09-08
PE20050665A1 (es) 2005-11-02
DE602004014020D1 (de) 2008-07-03
GT200400241A (es) 2005-10-31
US20050148560A1 (en) 2005-07-07
WO2005051401A2 (en) 2005-06-09
WO2005051401A3 (en) 2005-09-01
ATE395919T1 (de) 2008-06-15
EP1689410B1 (en) 2008-05-21
UY28630A1 (es) 2005-06-30
AR046672A1 (es) 2005-12-14
TW200530263A (en) 2005-09-16
PL1689410T3 (pl) 2008-10-31

Similar Documents

Publication Publication Date Title
AR005703A1 (es) Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen
BRPI0511396A (pt) derivados de retinal e métodos para uso no tratamento de enfermidades visuais
ECSP034924A (es) Derivados sustituidos del 1-oxa-2,8-daza-espiro[4,5]dec-2-eno
ECSP045407A (es) Benzazoles sustituidos y el uso del mismo como inhibidores de quinasa raf
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
AR059203A1 (es) Composiciones para uso vaginal
CL2008001920A1 (es) Composicion farmaceutica que comprende un inhibidor de la pde 2, un agonista del receptor selectivo e2 y un portador; y uso en el tratamiento de fractura y/o defecto oseo (div. sol. 3179-04).
ECSP066411A (es) Tienopirazoles
CR9591A (es) Inhibidores de proteina cinasa derivados de pirrol (2,3-b) piridina
SE0100901D0 (sv) New composition
AR045016A1 (es) Derivados de 5-carbamimidoi-2-metilsulfaniltiofen-3-sulfonil como inhibidores conjugados de la cascada de complemento y su uso en el tratamiento de enfermedades.
UY27732A1 (es) Uso de análogos del benzimidazol en el tratamiento de la proliferación celular.
DE60327994D1 (de) Ansamycine mit verbesserten pharmakologischen und biologischen eigenschaften
AR037771A1 (es) Moleculas pequenas para el tratamiento del crecimiento celular anormal
AR048878A1 (es) Composiciones topicas de metadona y metodos para usarlas
PA8618401A1 (es) Prevencion y tratamiento de enfermedades cardiacas hipertensivas mediante el uso de los estrogenos selectivos 8beta-vinil-estra-1,3,5(10)-trien-3,17beta-diol y 17beta-fluor-9alfa-vinil-estra-1.3,5(10)-trien-3,16alfa-diol
AR031975A1 (es) Compuestos analogos de (1r,cis)-4-(6-amino-9h-purin-9-il) -2-ciclopenteno-1-metanol, proceso para su preparacion, su uso en el tratamiento de infecciones virales, y envase que los contiene
UY31305A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen.
AR028579A1 (es) Metodo para el tratamiento de la sequedad vaginal, con agonistas del receptor de acetilcolina nicotinica
CL2007002392A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de hiperplasia prostatica benigna, enfermedad de barrett, asma, enfermedad de crohn, reparacion de musculo esqueletico y tendon, colitis ulcerosa y leishmaniasis.
CL2008003231A1 (es) Compuestos derivados de 1,3-dihidro-5-isobenzofurancarbonitrilo sustituido, inhibidores selectivos de la recaptacion de serotonina; composicion farmaceutica; procedimiento de preparacion; utiles en el tratamiento y/o prevencion de la eyaculacion prematura.
PT1228028E (pt) Sais de hidroxieicosatetraeniato, composicoes e metodos para utilizacao no tratamento de perturbacoes da secura ocular
UY29109A1 (es) Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios
ITRM20020529A1 (it) Polimeri sterilizzanti, processo di loro preparazione ed uso.
ECSP034531A (es) Derivados sustituidos de c-ciclohexilmetilamina